-
公开(公告)号：KR1020160132668A
公开(公告)日：2016-11-21
申请号：KR1020150065508
申请日：2015-05-11
Applicant: 전남대학교산학협력단
CPC classification number: Y02A50/481
Abstract: 본발명은암의효율적인치료를위해히알루론산분해효소(HAase)를암호화하는폴리뉴클레오티드가프로모터에작동가능하게연결된유전자컨스트럭트로형질전환되어상기히알루론산분해효소를발현하는약독화박테리아균주를유효성분으로함유하는암치료용약학적조성물을제공한다.
-
公开(公告)号：KR101548734B1
公开(公告)日：2015-09-01
申请号：KR1020130022219
申请日：2013-02-28
Applicant: 전남대학교산학협력단
CPC classification number: Y02A50/481
Abstract: 본발명은치료용약독화혐기성박테리아의항암효과를증가시키기위해, 약독화된살모넬라속 균주및 IL-1β(interleukin-1β)를포함하는, 암예방및 치료용조성물을제공한다.
-
公开(公告)号：KR101003149B1
公开(公告)日：2010-12-22
申请号：KR1020080108011
申请日：2008-10-31
Applicant: 전남대학교산학협력단
CPC classification number: A61B5/073 , A61M5/14276 , A61M31/002
Abstract: Provided are a bacterium-based microrobot for medical treatment, an operation method thereof, and a treatment method using the same. The bacterium-based microrobot can be propelled by the flagellum movement of bacteria, can be directed toward a target lesion by the ability of bacteria to recognize the lesion, can be monitored for how many the microrobot targets the lesion, and can directly or indirectly treat the lesion by the proliferation of bacteria through self-division in the lesion. The bacteria may be genetically manipulated to be resistant to immune responses and produce a material inhibitory of the growth of affected cells.
-
公开(公告)号：KR1020100048728A
公开(公告)日：2010-05-11
申请号：KR1020080108011
申请日：2008-10-31
Applicant: 전남대학교산학협력단
CPC classification number: A61B5/073 , A61M5/14276 , A61M31/002
Abstract: PURPOSE: A micro robot, an operating method thereof, and a treating method thereof are provided to directly treat lesion by using the perception and portability of bacteria. CONSTITUTION: A bacteria(200) is attached to a back side and a circumference of a microstructure(300). A picking unit(310) collects a blood sample in one side of the microstructure. A reaction agent unit(320) erupts reaction agent in order to observe the reaction of lesion and blood. A mixing unit mixes the blood and reaction agent. A diagnostic unit analyzes the mixture of the reaction agent and blood. A controlling unit determines processing results according to the result analyzed by the diagnostic unit. A drug unit sprays the drug according to the indication of the controller. An exhausting unit sprays the drug to the lesion.
Abstract translation: 目的：提供微型机器人及其操作方法及其处理方法，通过使用细菌的感知和便携性来直接治疗病变。 构成：细菌（200）附着在微结构（300）的背面和圆周上。 拾取单元（310）在微结构的一侧收集血样。 反应剂单元（320）喷射反应剂以观察病变和血液的反应。 混合单元混合血液和反应剂。 诊断单元分析反应剂和血液的混合物。 控制单元根据由诊断单元分析的结果确定处理结果。 药物单位根据控制者的指示喷洒药物。 排气装置将药物喷洒到病变处。
-
5.发明公开ｐｐＧｐｐ―결손 변이 살모넬라 갈리나룸 균을 포함하는 가금 티프스 약제학적 백신 조성물 无效用于包含PPGPP缺陷的沙门氏菌菌落变异的L L ATIONS ATIONS ATIONS ATIONS ATIONS ATIONS ATIONS ATIONS ATIONS ATIONS ATIONS
公开(公告)号：KR1020110126227A
公开(公告)日：2011-11-23
申请号：KR1020100045781
申请日：2010-05-17
Applicant: 전남대학교산학협력단
IPC: A61K39/112 , A61K39/02 , A61P37/00 , A61P43/00
CPC classification number: Y02A50/482 , Y02A50/484 , A61K39/0275 , A61K2039/522 , Y10S424/826
Abstract: PURPOSE: A pharmaceutical vaccine composition for fowl typhoid and a feed composition for preventing fowl typhoid are provided to induce prepare antibiotics and to effectively prevent or treat fowl typhoid. CONSTITUTION: A pharmaceutical vaccine composition for fowl typhoid contains ppGpp(guanosine 5'-diphosphate 3'-diphosphate)-deletion mutant Salmonella Gallinarum. The strain contains inactivated relA gene, spoT gene encoding ppGpp synthase, or activated relA gene and spoT gene. A feed composition for preventing fowl typhoid contains the ppGpp-deletion mutant Salmonella Gallinarum. The composition is manufactured in the form of a tablet, pill, powder, granule, capsule, suspension, emulsion, or syrup.
Abstract translation: 目的：提供用于禽类伤寒和用于预防家禽伤寒的饲料组合物的药物疫苗组合物，以诱导制备抗生素并有效预防或治疗家禽伤寒。 构成：用于禽类伤寒的药物疫苗组合物含有ppGpp（鸟苷5'-二磷酸3'-二磷酸）缺失突变体沙门氏菌（Salmonella Gallinarum）。 该菌株含有灭活的relA基因，编码ppGpp合酶的spoT基因，或活化的relA基因和spoT基因。 用于防止禽类伤寒的饲料组合物含有ppGpp缺失突变体沙门氏菌（Salmonella Gallinarum）。 组合物以片剂，丸剂，粉剂，颗粒剂，胶囊剂，悬浮液，乳剂或糖浆剂的形式制备。
-
Patent Agency Ranking
公开(公告)号：KR101711399B1
公开(公告)日：2017-03-03
申请号：KR1020117028233
申请日：2010-05-27
Applicant: 전남대학교산학협력단
IPC: A61K48/00 , C07K14/255 , A01K67/027 , A61K35/00
CPC classification number: A01K67/027 , A01K2207/12 , A01K2227/105 , A01K2267/0375 , A61K48/0033 , A61K2035/11 , C07K14/255 , C12N2830/001
Abstract: 본발명은경색조직에대하여특이적으로타겟팅되는박테리아및 그의용도에관한것이다. 본발명은경색조직선택적타겟팅박테리아를최초로제공하는것이며, 경색조직에약물을선택적으로운반하거나경색조직을선택적으로이미징하는데에적용된다. 본발명의경색-타겟팅박테리아는항생제를이용하여처리를종결시킬수 있기때문에, 재조합바이러스를이용하는유전자치료와비교하여상당한이점이있다. 본발명의경색-타겟팅박테리아는경색심근또는경색뇌에대한친화성및 특이성이매우높아, 심장이외의다른기관또는조직에서의소망하지않는트랜스펙션을크게줄일수 있도록한다. 본발명의경색-타겟팅박테리아에의한경색심근또는경색뇌에서의유전자발현은원격조절(remote control)이가능하다.
Abstract translation: 本发明涉及特异性靶向梗死组织的细菌及其应用。 本发明首次提供了选择性梗塞的组织靶向细菌，并且可以用于选择性地将药物递送至梗死组织或选择性地成像梗塞组织。 本发明的梗塞组织靶向细菌可以通过使用抗生素来完成治疗，因此与使用重组病毒的基因治疗相比具有显着的优点。 本发明的梗死组织靶向细菌对梗塞的心肌或梗死的脑具有显着高的亲和性和特异性，从而显着减少心脏以外的器官或组织中不期望的转染。 本发明的梗死组织靶向细菌在梗死心肌或梗死的脑中的基因表达是可远程控制的。
-
7.发明授权
公开(公告)号：KR101636882B1
公开(公告)日：2016-07-06
申请号：KR1020150090681
申请日：2015-06-25
Applicant: 전남대학교산학협력단
Abstract: 본발명은인간 ephrine A형수용체 2(hEphA2)에특이적으로결합하는, 서열번호 1 또는 2로표시되는아미노산서열로구성되는인간피브로넥틴도메인Ⅲ(Fn3) 유래펩타이드및 그의암진단등의용도에관한것이다.
Abstract translation: 本发明涉及与人类ephrin A型受体2（hEphA2）特异性结合的来自人纤连蛋白结构域III（Fn3）的肽，由序列号1或2表示的氨基酸序列形成。本发明 还涉及其用于诊断癌症的用途。
-
公开(公告)号：KR1020140107954A
公开(公告)日：2014-09-05
申请号：KR1020130022219
申请日：2013-02-28
Applicant: 전남대학교산학협력단
CPC classification number: Y02A50/481 , A61K38/20
Abstract: Provided in the present invention is a composition to prevent and treat cancer which comprises attenuated salmonella species strain and interleukin-1β (IL-1β) to increase an anticancer effect of attenuated anaerobic bacteria for treatment. According to an embodiment of the present invention formed like the same, a composition to prevent and treat cancer, and a treatment method using the same increasing the anticancer effect of the attenuated salmonella strain can be provided.
Abstract translation: 本发明提供了一种预防和治疗癌症的组合物，其包括减毒沙门氏菌菌株和白细胞介素-1β（IL-1β），以增加减毒厌氧细菌治疗的抗癌作用。 根据本发明的一个实施方案，可以提供预防和治疗癌症的组合物，以及使用该组合物增加减毒沙门氏菌菌株的抗癌作用的治疗方法。
-
9.发明授权Ｃｌｏｓｔｒｉｄｉｕｍ ｓｅｐｔｉｃｕｍ 알파 독소의돌연변이 단백질 및 이를 이용한 발작성 야간혈색소뇨증의진단방법 및 진단용 키트 失效脓胸梭菌α毒素的突变蛋白及其使用的阵发性夜间血红蛋白尿的诊断方法，以及含有该菌的诊断用试剂盒
公开(公告)号：KR100644232B1
公开(公告)日：2006-11-10
申请号：KR1020040020841
申请日：2004-03-26
Applicant: 전남대학교산학협력단
IPC: C12Q1/68
Abstract: 본 발명은 병원성 세균
Clostridium septicum 유래의 알파(alpha) 독소를 발현시키는 대장균 벡터를 제조한 후 부위특이적 돌연변이기술을 통하여 제조한 돌연변이 독소인 S190C/S239C 및 Y156G에 관한 것이다.
또한 본 발명은
C.
septicum 알파 독소의 돌연변이 단백질인 S190C/S239C 및 Y156G 독소를 사용하여 GPI 생합성 경로의 이상으로 인해 발생하는 발작성야간혈색소뇨증을 진단하는 방법 및 진단용 키트에 관한 것이다.
Clostridium septicum * 알파 독소 * S190C/S239C * Y156G * 발작성야간혈색소뇨증 * GPI 생합성 * 세포괴사 * 돌연변이 단백질-
公开(公告)号：KR1020110095528A
公开(公告)日：2011-08-25
申请号：KR1020100015048
申请日：2010-02-19
Applicant: 전남대학교산학협력단
IPC: A61K48/00 , A61K39/112 , A61P35/00
CPC classification number: Y02A50/482 , A61K49/0013 , A61K48/00 , C12N15/66 , G01N2800/7028
Abstract: PURPOSE: A tumor-specific imageable therapeutic agent is provided to monitor/diagnose cancer through image photographing. CONSTITUTION: A tumor imageable therapeutic agent contains ppGpp-deleted Samonella containing a cytotoxic gene and luminescence gene which are operatively linked to a inducible or tumor-specific promoter. The cytotoxic gene and luminescence gene are inserted to a plasmid or Salmonella gene. The luminescence gene is luciferase gene. The cytotoxic gene is ClyA gene. The tumor-specific promoter is amsB(asparaginase coding), pflE(pyruvate-formate-lyase activating enzyme coding), or pepT(tripeptidase coding). The inducible promoter is pBAD or pTET.
Abstract translation: 目的：提供肿瘤特异性可成像治疗剂，通过图像拍摄来监测/诊断癌症。 构成：肿瘤可成像治疗剂含有含有与可诱导或肿瘤特异性启动子有效连接的细胞毒性基因和发光基因的ppGpp缺失的Samonella。 将细胞毒性基因和发光基因插入质粒或沙门氏菌基因。 发光基因是荧光素酶基因。 细胞毒性基因是ClyA基因。 肿瘤特异性启动子是amsB（编码天冬酰胺酶），pflE（丙酮酸 - 甲酸裂合酶激活酶编码）或pepT（三肽酶编码）。 诱导型启动子是pBAD或pTET。
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.024 seconds)
